Finance

Lists
1276:HKG
Jiangsu Hengrui Pharmaceuticals Co Ltd
47,60 HKD
-0,83%
(-0,40) 1D
16 ოქტ, 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1276...
Open
48,00 HKD
High
49,30 HKD
Low
46,92 HKD
Mkt. cap
345,69 მლრ.
Avg. vol.
4,04 მლნ.
Volume
4,16 მლნ.
P/E ratio
34,86
52-wk high
84,50 HKD
52-wk low
43,02 HKD
EPS
1,37 HKD
No. of employees
21 ათ.
Open
48,00 HKD
High
49,30 HKD
Low
46,92 HKD
Mkt. cap
345,69 მლრ.
Avg. vol.
4,04 მლნ.
Volume
4,16 მლნ.
P/E ratio
34,86
52-wk high
84,50 HKD
52-wk low
43,02 HKD
EPS
1,37 HKD
No. of employees
21 ათ.
News stories
From web sources and news partners
Seeking Alpha
Seeking Alpha
·
59 წუთის წინ
SH: A Tactical Hedge, But Not Yet A Short Call (NYSEARCA:SH)
Yahoo Finance
Yahoo Finance
·
11 საათის წინ
Michael Burry Warns of a Stock Market ‘Supervolcano’
Profile
Jiangsu Hengrui Pharmaceuticals Company Ltd., also known as Jiangsu Hengrui, is a Chinese pharmaceutical company that manufactures and distributes various types of drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and related products. It is the largest listed pharmaceutical company in China. Wikipedia
About Jiangsu Hengrui Pharmaceuticals Co Ltd
CEO-
Employees20,7 ათ.
Founded1970
Headquarters-
SectorPharmaceutical industry
Next call 8 დღეში
სამ, 27 ოქტ, 09:00
Fiscal period
Q3 2026
- / 0,31 CNY
Revenue / Est. (CNY)
- / 9,17 მლრდ.
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
7,43 მლრდ.
8,44 მლრდ.
8,14 მლრდ.
7,32 მლრდ.
Cost of goods sold
1,07 მლრდ.
1,25 მლრდ.
1,09 მლრდ.
1,02 მლრდ.
Cost of revenue
1,07 მლრდ.
1,25 მლრდ.
1,09 მლრდ.
1,02 მლრდ.
Research and development expenses
1,72 მლრდ.
2,02 მლრდ.
1,65 მლრდ.
1,84 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,23 მლრდ.
3,01 მლრდ.
2,81 მლრდ.
2,78 მლრდ.
Operating expense
4,76 მლრდ.
5,35 მლრდ.
4,48 მლრდ.
4,61 მლრდ.
Total operating expenses
5,83 მლრდ.
6,60 მლრდ.
5,57 მლრდ.
5,63 მლრდ.
Operating income
1,60 მლრდ.
1,84 მლრდ.
2,57 მლრდ.
1,68 მლრდ.
Other non operating income
-154,21 მლნ.
145,74 მლნ.
-345,12 მლნ.
243,91 მლნ.
EBT including unusual items
1,36 მლრდ.
2,30 მლრდ.
2,56 მლრდ.
2,40 მლრდ.
EBT excluding unusual items
1,68 მლრდ.
1,91 მლრდ.
2,55 მლრდ.
1,60 მლრდ.
Income tax expense
55,51 მლნ.
338,85 მლნ.
275,87 მლნ.
211,27 მლნ.
Effective tax rate
4,08%
14,76%
10,79%
8,82%
Other operating expenses
-217,30 მლნ.
326,84 მლნ.
4,76 მლნ.
-5,09 მლნ.
Net income
1,30 მლრდ.
1,96 მლრდ.
2,28 მლრდ.
2,18 მლრდ.
Net profit margin
17,52%
23,22%
28,04%
29,84%
Earnings per share
0,20
-
-
-
Interest and investment income
242,14 მლნ.
288,66 მლნ.
322,96 მლნ.
448,28 ათ.
Interest expense
-689,68 ათ.
-2,00 მლნ.
-448,28 ათ.
-322,96 მლნ.
Net interest expenses
241,45 მლნ.
286,66 მლნ.
322,52 მლნ.
-322,52 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
1,78 მლრდ.
2,04 მლრდ.
2,77 მლრდ.
1,93 მლრდ.
Gain or loss from assets sale
2,31 მლნ.
-4,05 მლნ.
-
-40,62 მლნ.
AI content may include mistakes. Learn more
Google აპები